TET2 and acute myeloid leukemia: Recent studies have pointed towards TET2 mutations as predictive markers for lower OS or RFS in AML patients (Sasaki et al., 2020; Wang et al., 2020), which our study supported, indicating lower OS in elderly AML patients with TET2 mutations.